Item 2.02. Results of Operations and Financial Condition. OnAugust 3, 2021 ,Neurocrine Biosciences, Inc. announced its financial results for the second quarter endedJune 30, 2021 . The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. Exhibit Description 99.1 Press Release datedAugust 3, 2021 104 Cover Page Interactive Data File
--------------------------------------------------------------------------------
© Edgar Online, source